Renal Cancer - Results from #1580

Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. March 21, 2022

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. March 21, 2022

Can kidney parenchyma metabolites serve as prognostic biomarkers for long-term kidney function after nephrectomy for renal cell carcinoma? A preliminary study. March 18, 2022

Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. March 18, 2022

A Web-Based Prediction Model for Cancer-Specific Survival of Middle-Aged Patients With Non-metastatic Renal Cell Carcinoma: A Population-Based Study. March 17, 2022

Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. March 17, 2022

Sarcopenia and systemic inflammation are associated with decreased survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. March 16, 2022

Recent pharmacological approaches for the treatment of renal cell carcinoma. March 16, 2022

Safety and Oncologic Outcomes of Percutaneous Cryoablation of Renal Cell Carcinoma Recurrences in the Ipsilateral Kidney Following Partial Nephrectomy. March 15, 2022

Contrast-enhanced CT immediately following percutaneous microwave ablation of cT1a renal cell carcinoma: Optimizing cancer outcomes. March 15, 2022

The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma. March 14, 2022

Identification of Recurrent Anatomical Clusters Using Three-dimensional Virtual Models for Complex Renal Tumors with an Imperative Indication for Nephron-sparing Surgery: New Technological Tools for Driving Decision-making. March 14, 2022

Renal cell carcinoma in children and adolescents: A retrospective study of a French-Italian series of 93 cases. March 11, 2022

Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Factor in Patients Undergoing Nephrectomy for Non-Metastatic Renal Cell Carcinoma: Propensity Score Matching Analysis. March 11, 2022

Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi. March 10, 2022

Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. March 10, 2022

Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib. March 9, 2022

Construction of a Lactate-Related Prognostic Signature for Predicting Prognosis, Tumor Microenvironment, and Immune Response in Kidney Renal Clear Cell Carcinoma. March 9, 2022

The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. March 8, 2022

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. March 8, 2022

Page 80 of 456